2015


To access this material please log in or register

Register Authorize
2015/№2

The use of new oral anticoagulants during electric cardioversion in patients with non-valvular atrial fibrillation

Tatarsky B. A., Kazennova N. V.
Federal State Budgetary Institution “V. A. Almazov Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St.-Petersburg 197341

Keywords: anticoagulants, cardioversion, rivaroxaban, atrial fibrillation

DOI: 10.18087/rhj.2015.2.2064

The review presents possibilities of using new oral anticoagulants during cardioversion according to data of large, controlled, randomized studies. The authors discuss results of the first study on using rivaroxaban in patients with non-valvular atrial fibrillation during selective cardioversion.
  1. King DE, Dickerson LM, Sack JL. Acute management of atrial fibrillation: part II. prevention of thromboembolic complications. Am Fam Physician. 2002 Jul 15;66 (2):261–4.
  2. Weigner MJ, Caulfield TA, Danias PG et al. Risk for clinical thromboembolism associ¬ated with conversion to sinus rhythm in patients with atrial fibrillation lasting less than 48 hours. Ann Intern Med. 1997 Apr 15;126 (8):615–20.
  3. Stoddard MF, Dawkins PR, Prince CR, Ammash NM. Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiography study. J Am Coll Cardiol. 1995 Feb;25 (2):452–9.
  4. Gentile F, Elhendy A, Khandheria BK et al. Safety of electrical cardioversion in patients with atrial fibrillation. Mayo Clin Proc. 2002 Sep;77 (9):897–904.
  5. January CT, Wann LS, Alpert JS et al. 2014 AHA / ACC / HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology / American Heart Association task force on practice guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64 (21):e1–76.
  6. Nuotio I, Hartikainen JE, Grönberg T et al. Time to cardioversion for acute atrial fibrillation and thromboembolic complications. JAMA. 2014 Aug 13;312 (6):647–9.
  7. Stiles S. Earliest Is Best for Preventing Thromboembolism in No-Anticoagulant Acute AF Cardioversion: Cohort Study. MedScape. 2014 Aug 12. Available at: http://www.medscape. com / viewarticle / 829805.
  8. Camm AJ, Lip GY, De Caterina R et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special condition of the European Heart Rhythm Assotiation. Eur Heart J. 2012 Nov;33 (21):2719–47.
  9. Calkins H, Kuck KH, Cappato R et al. 2012 HRS / EHRA / ECAS Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012 Apr;14 (4):528–606.
  10. Prystowsky EN, Benson DW, Fuster V et al. Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. Circulation. 1996 Mar 15;93 (6):1262–77.
  11. Nagarakanti R, Ezekowitz MD, Oldgren J et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011 Jan 18;123 (2):131–6.
  12. Piccini JP, Stevens SR, Lokhnygina Y et al. Outcomes following cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. J Am Coll Cardiol. 2013 May 14;61 (19):1998–2006.
  13. Flaker G, Lopes RD, Al-Khatib SM et al. Efficacy and safety of apixa­ban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). J Am Coll Cardiol. 2014 Mar 25;63 (11):1082–7.
  14. Ezekowitz MD, Cappato R, Klein AL et al. Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvularaTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation under­going elective cardioversion. Am Heart J. 2014 May;167 (5):646–52.
  15. Cappato R, Ezekowitz MD, Klein AL et al. Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation. Eur Heart J. 2014 Dec 14;35 (47):3346–55.
Tatarsky B. A., Kazennova N. V. The use of new oral anticoagulants during electric cardioversion in patients with non-valvular atrial fibrillation. Russian Heart Journal. 2015;14 (2):104–109

To access this material please log in or register

Register Authorize
Ru En